MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A
532
$42.63
$1.03
(2.36%)
| Watchers | 532 |
| 52-Wk Low | $24.31 |
| 52-Wk High | $64.98 |
| Market Cap | $2.68B |
| Volume | 125,721.00 |
| 52-Wk High | $64.98 |
| 52-Wk Low | $24.31 |
TimesSquare Capital Management LLC Has $23.44 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Ticker Report • about 2 months ago
TimesSquare Capital Management LLC raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) by 1,270.7% in the 3rd quarter, according to the company in its most recent...
Share to Feed
MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the...
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Analysts at HC Wainwright raised their Q1 2024 earnings estimates for MoonLake Immunotherapeutics in a note issued to investors...
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Stock analysts at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for shares of MoonLake...
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) HC Wainwright issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on...
Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm...
Invesco Ltd. lowered its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) by 4.4% in the third quarter, according to its most recent filing with the Securities and...
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024...
MoonLake Immunotherapeutics (NASDAQ:MLTX Get Free Report)s stock had its buy rating reissued by equities researchers at Needham & Company LLC in a research report issued...
MoonLake Immunotherapeutics (NASDAQ:MLTX Get Free Report) shares shot up 7.6% during trading on Friday following a stronger than expected earnings report. The stock traded as high as $52.23...